STAT reporters discuss why a looming patent cliff could lead to more pharmaceutical deal-making and a new obesity startup.

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Greater Boston's life sciences leaders will find out in 2025 if their industry can overcome its post-pandemic slump — and how ...

The move will place students in good stead to take up skilled roles in biopharma manufacturing. Read more at straitstimes.com ...

A new study from the Tippie College of Business finds that many drug prices actually drop after pharmaceutical company ...

Araris will use its linker technology to generate multi-warhead ADCs for “undisclosed targets” provided by Chugai.

Look for renewed investment driven by lower interest rates in the new year, and a continued focus on late-stage assets, ...

Drug pricing is influenced by numerous factors, but technology has the potential to strike the critical balance between ...

Former Head of Global R&D at Bayer AG and an exceptional leader with a wealth of experience across biopharma Pivotal time of transition as the company ...

The typical cost of developing new medications may not be as high as generally believed, with a few ultra-costly medications skewing public discussions about the cost of pharmaceutical research and ...

GenScript Biotech Corporation, a global leader in life sciences research and manufacturing services, has officially joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner. This ...

The typical cost of developing new medications may not be as high as generally believed, with a few ultra-costly medications ...